nhibitor of the transporter P-glycoprotein (P-gp). Sofosbuvir is a substrate of P-gp. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp inhibitors; however, if these drugs are given together, consider increased monitoring for potential adverse effects. Caution is warranted when ritonavir is administered with sofosbuvir as there is a potential for elevated concentrations of sofosbuvir. Ritonvir is an inhibitor of the transporter P-glycoprotein (P-gp). Sofosbuvir is a substrate of P-gp. According to the manufacturer, no dosage adjustments are required when sofosbuvir is administered concurrently with P-gp inhibitors; however, if these drugs are given together, consider increased monitoring for potential adverse effects.
Lovastatin: Use caution when administering velpatasvir with lovastatin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp).
Lovastatin; Niacin: Use caution when administering velpatasvir with lovastatin. Taking these medications together may increase the plasma concentrations of both drugs, potentially resulting in adverse events. Both drugs are substrates and inhibitors of the drug transporter P-glycoprotein (P-gp).
Luliconazole: Theoretically, luliconazole may increase the serum concentrations of velpatasvir. Luliconazole is a weak in vitro CYP3A4 inhibitor at therapeutic concentrations; velpatasvir is a substrate of CYP3A4.
Lumacaftor; Ivacaftor: Avoid coadministration of velpatasvir with lumacaftor; ivacaftor. Taking these drugs together may significantly decrease plasma concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy. Lumacaftor is a potent inducer of CYP3A4; velpatasvir is a CYP3A4 substrate. In addition, velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); lumacaftor is an inducer/inhibitor of P-gp. Although the clinical significance of this interaction is unknown, concurrent use of sofosbuvir and lumacaftor; ivacaftor may alter sofosbuvir exposure; caution and close monitoring are advised if these drugs are used together. Sofosbuvir is a substrate of the drug transporter P-glycoprotein (P-gp). In vitro data suggest that lumacaftor; ivacaftor has the potential to both induce and inhibit P-gp. The net effect of lumacaftor; ivacaftor on P-gp transport is not clear, but substrate exposure may be affected leading to decreased efficacy or increased or prolonged therapeutic effects and adverse events. FDA-approved labeling for sofosbuvir recommends to avoid coadministration with potent P-gp inducers.
Lumacaftor; Ivacaftor: Avoid coadministration of velpatasvir with lumacaftor; ivacaftor. Taking these drugs together may significantly decrease plasma concentrations of velpatasvir, potentially resulting in loss of antiviral efficacy. Lumacaftor is a potent inducer of CYP3A4; velpatasvir is a CYP3A4 substrate. In addition, velpatasvir is a substrate of the drug transporter P-glycoprotein (P-gp); lumacaftor is an inducer/inhibitor of P-gp. Use caution when administering velpatasvir with ivacaftor. Taking these drugs together may increase the plasma concentrations of velpatasvir, potentially resulting in adverse events. Velpatasvir is a substrate of the drug transporter P-glycoprotein (P-g |
